

### ***Remarks***

Upon entry of the foregoing amendment, claims 1-35 are pending in the application, with 1, 11, 13, 20, 24, 26, 27, 30, 32, 34, and 35 being the independent claims. The amendments to claims 4, 6, 9, 10, 12-19, and 31-34 are made to eliminate improper multiple dependencies and to place the claims in proper format for examination. Support for the amendments to the claims is found in the claims as originally filed. These changes are believed to introduce no new matter, and their entry is respectfully requested.

The specification has been amended to direct the entry of a substitute Sequence Listing. The Sequence Listing has been amended to include the proper descriptive terms for the combined DNA/RNA sequences listed as SEQ ID NOS: 6-11. In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter.

It is our understanding that 37 C.F.R. § 1.821(f) does not apply when a Sequence Listing is being filed electronically, and that it is neither necessary nor appropriate to state that the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing are the same.

### ***Conclusion***

Prompt and favorable consideration of this Preliminary Amendment is respectfully requested. Applicants believe the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will

expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert A. Schwartzman, Ph.D.  
Attorney for Applicants  
Registration No. 50,211

Date: February 12, 2007

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600  
584967\_1.DOC